The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials

The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials

Background: This paper aimed to evaluate the effectiveness of incorporating CDK 4/6 inhibitors (CDK4/6i) into ET for the adjuvant treatment of HR + HER2-resected early-stage breast cancer (ESBC) patients, employing meta-analysis. Methods: In this paper, we compiled randomized clinical trials focusin...

Full description

Saved in:
Bibliographic Details
Main Authors: Merve Keskinkilic, Mehmet Emin Arayici, Yasemin Basbinar, Hulya Ellidokuz, Tugba Yavuzsen, Ilhan Oztop
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Breast
Subjects:
Palbociclib
Ribociclib
Abemaciclib
Meta-analysis
CDK4/6 inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977624001462
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items